scispace - formally typeset
A

Ajit Varki

Researcher at University of California, San Diego

Publications -  557
Citations -  63836

Ajit Varki is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Sialic acid & SIGLEC. The author has an hindex of 124, co-authored 542 publications receiving 58772 citations. Previous affiliations of Ajit Varki include Emory University & National Institute of Advanced Industrial Science and Technology.

Papers
More filters

Cellular Organization of Glycosylation

TL;DR: This article provided an overview of glycosylation from the perspective of a single cell, taking into account the patterns of expression, topology, and other features of the biosynthetic and degradative enzymes that are common to most cell types.
Journal ArticleDOI

Sialic Acid 9-O-Acetylation on Murine Erythroleukemia Cells Affects Complement Activation, Binding to I-type Lectins, and Tissue Homing

TL;DR: It is demonstrated that cell surface 9-O-acetylation can affect a variety of biological recognition phenomena and provide a system for further exploration of the specific molecular mechanisms involved.
Journal ArticleDOI

Human-specific expression of Siglec-6 in the placenta

TL;DR: It is speculated that the negative signaling potential of Siglec-6 was recruited to human-specific placental expression, to slow the tempo of the human birth process, as leptin-deficient mice have increased parturition times.
Journal ArticleDOI

Host adaptation of a bacterial toxin from the human pathogen salmonella typhi.

TL;DR: The atomic structure of typhoid toxin bound to Neu5Ac reveals the structural bases for its binding specificity and provides insight into the molecular bases for Salmonella Typhi's host specificity and may help the development of therapies for typhoid fever.
Journal ArticleDOI

Typhlitis in acute leukemia: successful treatment by early surgical intervention.

TL;DR: A patient in whom the clinical diagnosis of typhlitis led to early operation, with intensive blood component support, is reported, suggesting that such an approach might improve the usually grim prognosis in patients whose underlying malignancy offers a clear chance for remission.